Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | GIPR | P48546 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651344 | 0.85 | LSS (0.39) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2655938 | 0.83 | HDAC1 (0.46) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2651633 | 0.81 | GCGR (0.66) | EPHX2NR1H4GLP1RGCGRGIPR | |
| SCHEMBL2643784 | 0.78 | GCGR (0.51) | EPHX2NR1H4HDAC8HDAC6GLP1R | |
| SCHEMBL2644845 | 0.78 | CA1 (0.53) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2651759 | 0.78 | EPHX2 (0.46) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| Hydrochloric Acid SCHEMBL2644250 | 0.77 | CA1 (0.52) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2643761 | 0.77 | EPHX2 (0.47) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2643187 | 0.75 | CA1 (0.53) | EPHX2NR1H4MEN1KMT2ARAB9A | |
| SCHEMBL2643233 | 0.75 | PTGES (0.63) | EPHX2NR1H4HDAC3GLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | EPHX2 2953/4885NR1H4 107/4885MEN1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.